Pricing medicines: Theory and practice, challenges and opportunities

Nature Reviews Drug Discovery

Volumn 4, Issue 2, 2005, Pages 121-130

  Gregson, Nigel ^a   Sparrowhawk, Keiron ^b   Mauskopf, Josephine ^c   Paul, John ^c  

^a PriceSpective LLC   (United States)

^b PriceSpective Ltd   (United Kingdom)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARDIOVASCULAR AGENT; CELECOXIB; CIMETIDINE; CORTICOSTEROID; FINASTERIDE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIMECROLIMUS; PIOGLITAZONE; ROFECOXIB; ROSIGLITAZONE; TACROLIMUS;

ARTHRITIS; ATOPIC DERMATITIS; CLINICAL PRACTICE; COMPETITION; COST CONTROL; DRUG CLASSIFICATION; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; EPILEPSY; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE COST; HUMAN; INTERNATIONAL COOPERATION; LICENSING; LIFESPAN; MEDICAL TECHNOLOGY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS;

EID: 14044263603     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1633     Document Type: Review

References (11)

1. Congressional Record, H2701-H2702, 6 May 2004.
2. MEDTAP International. The Value of Investment in Health Care: Better Care, Better Lives. Executive Summary (MEDTAP, Bethesda, Maryland, 2003) [online] (2004).
3. WHO Collaborating Centre for Drug Statistics Methodology [online] (2004).
4. Gold, M. R., Siegel, J. E., Russell, L. B. & Weinstein, M. C. (eds) Cost-effectiveness in Health and Medicine (Oxford Univ. Press, New York, 1996).
5. Drummond, M. F., O'Brien, B., Stoddart, G. & Torrance, G. W. Methods for the Economic Evaluation of Health Care Programmes 2nd edn (Oxford Univ. Press, Oxford, 1997).
6. Garrison, L. et al. The drug budget silo mentality in Europe. Value in Health 6, s1 (2003).
7. Pharmaceutical Research and Manufacturers of America. New Drug Approvals in 2001 (PhRMA, Washington DC, 2002).
8. Kanavos, P., Costa-i-Font, J., Merkur, S. & Gemmill, M. The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis. LSE Health and Social Care Special Research Paper (London School of Economics and Political Science, 2004).
9. West, P. & Mahon, J. Benefits to Payers and Patients from Parallel Trade (York Health Economics Consortium, Univ. of York, 2003).
10. Paul, J. E. & Trueman, P. 'Fourth hurdle reviews', NICE, and database applications. Pharmacoepidemiol. Drug Saf. 10, 429-438 (2001).
11. Nagle, T. T. & Holden, R. K. The Strategy and Tactics of Pricing (Prentice Hall, New Jersey, 2002).